NCT02314780View on ClinicalTrials.gov

The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 29, 2015

Primary Completion Date

June 13, 2017

Study Completion Date

June 13, 2017

Conditions
Myocardial Ischemia
Interventions
DRUG

Heme arginate 3mg/kg

DRUG

Heme arginate 1mg/kg

DRUG

Placebo

Trial Locations (1)

1090

Medical University of Vienna, Vienna

Sponsors

Collaborators (1)

Orphan Medical
All Listed Sponsors
collaborator

National Bank of Austria

OTHER_GOV

collaborator

Orphan Medical

INDUSTRY

lead

Martin Andreas, M.D.

OTHER

NCT02314780 - The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart | Biotech Hunter | Biotech Hunter